GTHX - יחס מהיר G1 Therapeutics Inc.

G1 Therapeutics, Inc. (GTHX) relies on developing methods to reduce chemotherapy side effects, which ensures stable demand for its products. The company maintains a strong roster of scientists through the successful commercialization of drugs while strategically enhancing its logistics. The market trend visualized in monetary terms with the 2.18 indicator confirms its leadership in myelopreservation thanks to the unique bone marrow-protecting drug Cosela.

G1 Therapeutics, Inc. (GTHX) revenues depend on the commercial success of the oncology drug COSELA in the US market. The trend in the acid-test ratio reflects the company's ability to cover short-term liabilities using cash and accounts receivable. This metric intentionally excludes inventory, assessing only the most liquid assets. Analysis of this chart allows for the identification of cash flow gap risks or excessive capital freezing in non-performing balances.